Skip to main content


Treatment for Acute Coronary Syndrome, Coronary Artery Disease, Cardiovascular Risk Reduction, Ischemic Stroke, Prophylaxis

Update: Brilinta (ticagrelor) Now FDA Approved - July 20, 2011

US FDA Assigns New PDUFA Date for Brilinta (ticagrelor tablets)

WILMINGTON, Del.-- Feb 4, 2011 - AstraZeneca announced today that the US Food and Drug Administration (FDA) has acknowledged receipt of the company's reply to the Complete Response Letter (CRL) for the ticagrelor New Drug Application (NDA). Accordingly, the agency has accepted AstraZeneca's resubmission of the ticagrelor NDA, categorized it as a Class 2 resubmission to the CRL, and set a new PDUFA date of July 20, 2011.

The FDA issued the CRL on December 16, 2010. On January 21, 2011, AstraZeneca announced it had submitted the requested supplementary analyses as part of its CRL response.

AstraZeneca remains confident in the NDA submission for ticagrelor and will continue working with the FDA to progress towards completing the review of the NDA for ticagrelor.

About Brilinta (ticagrelor tablets)

Brilinta is an oral antiplatelet treatment for acute coronary syndromes (ACS). Brilinta is a direct-acting P2Y12 receptor antagonist in a chemical class called cyclopentyltriazolopyrimidines (CPTPs). Brilinta is the first reversibly-binding oral ADP receptor antagonist.

Brilinta is currently under regulatory review in 21 countries, including the US. The product has been approved in 30 countries, including in the EU, Iceland, and Norway, under the trade name Brilique and in Brazil under the trade name Brilinta.

Brilinta and Brilique are trademarks of the AstraZeneca group of companies.

About the PLATO study

PLATO was a large (18,624 patients in 43 countries) head-to-head patient outcomes study of ticagrelor versus clopidogrel, designed to establish whether ticagrelor could improve cardiovascular (CV) outcomes in ACS patients, compared to clopidogrel. The NDA submission for ticagrelor is based on the results of a comprehensive clinical trial programme, including data from the PLATO study.


The Prescription Drug User Fee Act (PDUFA) allows the FDA to collect fees from companies that produce certain human drug and biological products, including when an NDA is submitted. It is usual for the FDA to set a PDUFA goal date when responding to an NDA.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion healthcare business.

For more information about AstraZeneca in the US or the AZ&Me™ Prescription Savings programs, please visit: or call 1-800-AZandMe (292-6363).

Contact: AstraZeneca
Media Inquiries UK
Neil McCrae, +44 20 7604 8236 (24 hours)
Sarah Lindgreen, +44 20 7604 8033 (24 hours)
Abigail Baron, +44 20 7604 8034 (24 hours)
Media Inquiries US
Emily Denney, +1 302 885 3451 (US)
Kate Childress, +1 302 885 8217, mob: +1 302 290 7242 (US)
Investor Inquiries UK
Jonathan Hunt, +44 20 7604 8122, mob: +44 7775 704032
Karl HÃ¥rd, +44 20 7604 8123, mob: +44 7789 654364
Nicklas Westerholm, +44 20 7604 8124, mob: +44 7585 404950
Investor Inquiries US
Ed Seage, +1 302 886 4065, mob: +1 302 373 1361
Jorgen Winroth, +1 212 579 0506, mob: +1 917 612 4043

Related Articles

Brilinta (ticagrelor) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.